Company Filing History:
Years Active: 2020-2024
Title: Eunhee Kim: Innovator in GPCR Heteromer Inhibitors
Introduction
Eunhee Kim is a prominent inventor based in Seoul, South Korea. She has made significant contributions to the field of cancer research through her innovative work on G protein-coupled receptor (GPCR) heteromer inhibitors. With a total of 2 patents, her inventions are paving the way for new therapeutic approaches in oncology.
Latest Patents
Eunhee Kim's latest patents focus on GPCR heteromer inhibitors and their applications in cancer treatment. These inventions specifically target inhibitors of CXC receptor 4 (CXCR4)-G protein-coupled receptor (GPCR) heteromers. The research highlights the functional heteromer formed between CXCR4 and other GPCRs, which, when co-stimulated with specific agonists, enhances signaling pathways associated with cancer progression. The patents also detail the use of inhibitors that target the interacting GPCR partner of the CXCR4-GPCR heteromer, as well as specific antibodies that can be utilized in cancer diagnosis and therapy.
Career Highlights
Eunhee Kim is currently associated with GPCR Therapeutics, Inc., where she continues to advance her research in GPCR heteromers. Her work is instrumental in developing novel therapeutic strategies that could significantly impact cancer treatment.
Collaborations
Eunhee collaborates with notable colleagues, including DongSeung Seen and Jae-Yeon Jeong, who contribute to her research endeavors. Their combined expertise enhances the potential for groundbreaking discoveries in the field.
Conclusion
Eunhee Kim's innovative work in GPCR heteromer inhibitors represents a significant advancement in cancer research. Her contributions are expected to lead to new therapeutic options that could improve patient outcomes in oncology.